Načítá se...
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (CR) to treatment is infrequently reported. C...
Uloženo v:
| Vydáno v: | Cancer Commun (Lond) |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6020209/ https://ncbi.nlm.nih.gov/pubmed/29941039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-018-0312-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|